Erufosine
Erufosine is an inhibitor of PI3K/Akt and Ras/Raf/MAPK signaling pathways. Erufosine inhibits the activity of breast cancer cell lines MCF-7 and MDA-MB 231 (IC50: 40.95/40.8 μM) . Erufosine reduces the phosphorylation of PI3K (p85), Akt (PKB), and cRaf. Erufosine can be used in the study of breast cancer and myeloid leukemia[1].
Product Specifications
CAS Number
202867-33-2
Product Name Alternative
ErPC3; Erucylphosphohomocholine
UNSPSC
12352128
Target
Akt; p38 MAPK; PI3K; Raf; Ras
Related Pathways
GPCR/G Protein; MAPK/ERK Pathway; PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
CCCCCCCC/C=C\CCCCCCCCCCCCOP(OCCC[N+](C)(C)C)([O-])=O
Molecular Formula
C28H58NO4P
Molecular Weight
503.74
References & Citations
[1]Dineva IK, et al. Erufosine suppresses breast cancer in vitro and in vivo for its activity on PI3K, c-Raf and Akt proteins. J Cancer Res Clin Oncol. 2012 Nov;138 (11) :1909-17.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LC403149 20 µg
DARPP32 (PPP1R1B) (NM_032192) Human Over-expression Lysate
Sign In for Pricing
View Details 
BNC742843-100 1x 100 µL
SIGLEC1 / CD169 / Sialoadhesin (HSn 7D2), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
